Day 10: After confirming the production of antibodies in mice without causing disease, the team began designing the vaccine prototype. This involved choosing adjuvants, substances that enhance the body's immune response to the vaccine, and stabilizers to prolong the vaccine's shelf-life.
Day 11-12: The vaccine prototype was then tested on a small group of healthy adult volunteers from the hospital staff, starting with low doses. These initial human trials were critical to ensure that the vaccine did not cause adverse reactions in humans.
Day 13: With no immediate adverse reactions observed, the dosage was gradually increased. Volunteers were monitored for any signs of illness or discomfort.
Day 14: Two weeks into the process, the early morning hours were spent analyzing the data from the human trials. The team looked for evidence of an immune response similar to that observed in the mice…
